Latest & greatest articles for Travelers Diarrhea

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Travelers Diarrhea or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Travelers Diarrhea and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Travelers Diarrhea

1. Rifamycin (Aemcolo) - To treat travelers? diarrhea

Rifamycin (Aemcolo) - To treat travelers? diarrhea Drug Approval Package: AEMCOLO (rifamycin) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: AEMCOLO (rifamycin) Company:Cosmo Technologies, Inc. Application Number: 210910Orig 1 Approval Date: 11/16/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF

2019 FDA - Drug Approval Package

2. Diarrhoea - prevention and advice for travellers

% of episodes last for longer than 1 week, 5% persist for longer than 2 weeks, and 1% have a duration of more than 30 days [ ]. Prolonged diarrhoeal symptoms are more likely if the person is immunocompromised or has a protozoal infection. Protozoal diarrhoea can persist for weeks to months without treatment [ ]. Management Management : covers the prevention of travellers' diarrhoea, and advice for people who are at risk of travellers' diarrhoea. Scenario: Diarrhoea - prevention and advice for travellers (...) a diarrhoeal illness might severely impact on their health. Have a history of significant long-term morbidity after an enteric infection (for example reactive arthritis). Are undertaking critical trips in which a short bout of diarrhoea could severely impact the purpose of the trip (for example athlete, politician, professional musician, lecturer). May not have access to adequate medical treatment if they experience complicated travellers' diarrhoea. Basis for recommendation Basis for recommendation

2019 NICE Clinical Knowledge Summaries

3. Review: chronic and persistent diarrhea with a focus in the returning traveler Full Text available with Trip Pro

Review: chronic and persistent diarrhea with a focus in the returning traveler Travelers' diarrhea is a common malady afflicting up to 50% of travelers after a 2-week travel period. An appreciable percentage of these cases will become persistent or chronic. We summarized the published literature reporting persistent/chronic diarrhea in travelers elucidating current understanding of disease incidence, etiology and regional variability.We searched electronic databases (Medline, Embase (...) heterogeneity statistics, graphically represented with Forest plots.We identified 19 studies meeting the inclusion criteria (all published after 1999). 18 studies reported upon the incidence of persistent/chronic diarrhea as a syndromic diagnosis in returning travelers; one study reported adequate denominator data from which to assess pathogen specific etiology. Giardiasis comprise an appreicaible percentage of infectious mediated persistent/chronic diarrhea in returning travelers. The overall estimate

2017 Tropical diseases, travel medicine and vaccines

4. Traveller's diarrhoea

Traveller's diarrhoea Traveller's diarrhoea - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Traveller's diarrhoea Last reviewed: February 2019 Last updated: November 2017 Summary Occurs in 20% to 50% of people travelling to a less developed country, due to contaminated food or water, usually within the first 2 weeks of exposure. Prevention strategies include careful selection of food and beverages. Treatment (...) at the onset of diarrhoea with either quinolone antibiotics, azithromycin, or rifaximin, in addition to the use of loperamide, will quickly alleviate symptoms of bacterial traveller's diarrhoea. Quinolone resistance is a growing problem, particularly in Campylobacter infections acquired in south and SE Asia, where azithromycin is a better treatment choice than ciprofloxacin. Definition Traveller's diarrhoea (TD) is defined as ≥3 unformed stools in 24 hours accompanied by at least 1 of the following: fever

2017 BMJ Best Practice

6. Summary of the Committee to Advise on Tropical Medicine and Travel (CATMAT) statement on travellers' diarrhea

and harms based on available evidence on antimicrobial resistance patterns. "Best practice" recommendations for prevention of travellers' diarrhea CATMAT suggests Handwashing with soap and water before preparing meals, before eating meals, and after urination or defecation. Alcohol-based hand sanitizers may aid in reducing the risk of diarrheal illness among travellers. Consumption of undercooked or raw meats and seafood , and unpasteurized eggs and dairy products are best avoided. Foods cooked earlier (...) of a global survey. J Travel Med. 2004 Jul-Aug;11(4):231-7. Footnote 6 Steffen R, Collard F, Tornieporth N, Campbell-Forrester S, Ashley D, Thompson S, et al. Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica. JAMA. 1999 Mar 3;281(9):811-7. Footnote 7 DuPont HL. Systematic review: The epidemiology and clinical features of travellers' diarrhoea. Aliment Pharmacol Ther. 2009 Aug;30(3):187-96. Footnote 8 Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on Travellers

2015 CPG Infobase

7. Management of traveller's diarrhoea with a combination of sodium butyrate, organic acids, and A-300 silicon dioxide. Full Text available with Trip Pro

Management of traveller's diarrhoea with a combination of sodium butyrate, organic acids, and A-300 silicon dioxide. Traveller's diarrhoea (TD), defined by UNICEF/WHO as three or more unformed stools with or without other symptoms, imposes a considerable burden on travellers from developed countries. Various efforts have focused on decreasing the prevalence and severity of this condition.To assess the efficacy of a combination of sodium butyrate, organic acids, and A-300 silicon dioxide (...) in treatment providing symptomatic relief of TD.The study was conducted in accordance with a protocol presented to the Bioethical committee of Poznan University of Medical Sciences. A total of 278 patients travelling to countries with higher risk of diarrhoea for at least 10 days were divided into a study arm being administered, in case of TD, a combination of sodium butyrate, organic acids, and A-300 silicon dioxide (n = 139) and a placebo arm (n = 139) with placebo administration.Forty-seven patients

2014 Przeglad gastroenterologiczny Controlled trial quality: uncertain

8. Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis

Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

9. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. (Abstract)

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Enterotoxigenic Escherichia coli (ETEC) is a major cause of travellers' diarrhoea. We investigated the rate of diarrhoea attacks, safety, and feasibility of a vaccine containing heat-labile enterotoxin (LT) from ETEC delivered to the skin by patch in travellers to Mexico and Guatemala.In this phase II study, healthy adults (aged (...) 18-64 years) who planned to travel to Mexico or Guatemala and had access to a US regional vaccination centre were eligible. A centralised randomisation code was used for allocation, which was masked to participants and site staff. Primary endpoints were to investigate the field rate of ETEC diarrhoea, and to assess the safety of heat-labile toxins from E coli (LT) delivered via patch. Secondary endpoints included vaccine efficacy against travellers' diarrhoea and ETEC. Participants were

2008 Lancet Controlled trial quality: predicted high

10. Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: a systematic review and meta-analysis

Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

11. Development of a travelers' diarrhea vaccine for the military: how much is an ounce of prevention really worth?

Development of a travelers' diarrhea vaccine for the military: how much is an ounce of prevention really worth? Development of a travelers' diarrhea vaccine for the military: how much is an ounce of prevention really worth? Development of a travelers' diarrhea vaccine for the military: how much is an ounce of prevention really worth? Riddle MS, Tribble DR, Cachafiero SP, Putnam SD, Hooper TI Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the cost-effectiveness of a multiplex vaccine and pathogen-specific vaccines for the prevention of diarrhoea in travellers. The authors concluded that the vaccines against Campylobacter and enterotoxigenic Escherichia coli appeared to be more favourable than

2008 NHS Economic Evaluation Database.

12. Rifaximin: A useful drug for travelers’ diarrhea

Rifaximin: A useful drug for travelersdiarrhea Rifaximin: A useful drug for travelersdiarrhea – Clinical Correlations Search Rifaximin: A useful drug for travelersdiarrhea September 28, 2007 4 min read | | Sites We Follow: Useful Links: Questions? Comments? Contact us! © New York University. All rights reserved. Electronic ISSN 1944-0030. The content of this site is intended for health care professionals.

2007 Clinical Correlations

13. Statement on persistent diarrhea in the returned traveller

problems after travel to developing countries. J Infect Dis 1987;156:84-91. Footnote 5 Addiss DG, Tauxe RV, Bernard KW. Chronic diarrhoeal illness in US Peace Corps volunteers. Int J Epidemiol 1990;19:217-8. Footnote 6 Msengi AE, Phillips AD, Risdon RA et al. Travellers' diarrhoea among children returning to the United Kingdom from visits abroad. Ann Trop Paediatr 1998;8:173-80. Footnote 7 Pitzinger B, Steffen R, Tschopp A. Incidence and clinical features of traveler's diarrhea in infants and children (...) be advocated for acute traveller's diarrhea (TD). However, even when empiric therapy is initiated, medical assistance should be sought for investigation and management as soon as possible when the patient is very ill (e.g., high fever, prostration, severe abdominal pain), has a significant underlying medical illness, is immunodeficient, or has bloody stools. In practice, the majority of diarrheal episodes resolve, even without treatment, after a period of between hours and weeks. However, noticeable

2006 CPG Infobase

14. Statement on new oral cholera and travellers' diarrhea vaccination

EG, Sanchez JL, Mathewson IJ et al. Safety, Immunogenicity, and Protective Efficacy of the Whole-Cell/Recombinant B Subunit (WC/rBS) Oral Cholera Vaccine Against Travelers' Diarrhea. J Travel Med 1995;2(1):22-7. Peltola H, Siitonen A, Kyronseppa H et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991;338(8778):1285-9. Committee to Advise on Tropical Medicine and Travel (CATMAT) and the National Advisory Committee on Immunization (NACI). Preliminary (...) Statement on new oral cholera and travellers' diarrhea vaccination ARCHIVED - Statement on New Oral Cholera and Travellers' Diarrhea Vaccination - Canada.ca Language selection Search Search Canada.ca Search Menu Main Menu You are here: ARCHIVED - Statement on New Oral Cholera and Travellers' Diarrhea Vaccination We have archived this page and will not be updating it. You can use it for research or reference. We have archived this page and will not be updating it. You can use it for research

2005 CPG Infobase

15. Antibiotic treatment for travellers' diarrhoea. Full Text available with Trip Pro

Antibiotic treatment for travellers' diarrhoea. Traveller's diarrhoea is a syndrome frequently encountered in persons crossing an international boundary. Diarrhoea can lead to significant discomfort and interference with travel plans. Bacterial pathogens are a frequent cause of this syndrome. Several antibiotics have been tested for efficacy in reducing the duration and severity of the illness.The aims of this review were to assess the effects of antibiotics on traveller's diarrhoea in relation (...) to duration of illness, severity of illness, and adverse effects of medications.The Cochrane Collaboration Trials Register, MEDLINE, and EMBASE were searched. Additional trials were identified by hand searching. Content experts were contacted.All trials in any language in which travellers older than 5 years were randomly allocated to treatment for acute non-bloody diarrhoea with antibiotics and where the causative organism is not known at allocation.Two reviewers assessed trial quality and extracted

2000 Cochrane

16. Treatment of traveller's diarrhoea: economic aspects

assessment of the primary studies included in the study, the results may need to be treated with some caution. The issue of generalisability to other settings or countries was not addressed. Source of funding None stated. Bibliographic details Thomson M A, Booth I W. Treatment of traveller's diarrhoea: economic aspects. PharmacoEconomics 1996; 9(5): 382-391 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Diarrhea /economics /epidemiology /therapy; Humans; Travel AccessionNumber 21996008265 (...) Treatment of traveller's diarrhoea: economic aspects Treatment of traveller's diarrhoea: economic aspects Treatment of traveller's diarrhoea: economic aspects Thomson M A, Booth I W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health

1996 NHS Economic Evaluation Database.

17. Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea. (Abstract)

Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea. Diarrhoea is the most common illness affecting travellers to developing countries. Our study was designed to compare the efficacy of a single 500 mg dose of ciprofloxacin with placebo for treatment of acute diarrhoea in travellers. British troops who were within their first 8 weeks of deployment in Belize and who presented within 24 h of the onset of diarrhoea, were randomized to receive either ciprofloxacin 500 mg (...) of ciprofloxacin was an effective empirical treatment for reducing the duration and severity of diarrhoea in travellers. The regimen should maximise compliance and reduce the cost and duration of therapy.

1994 Lancet Controlled trial quality: predicted high

18. Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. (Abstract)

Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. To evaluate a poorly absorbed antimicrobial with in vitro activity against all major bacterial enteropathogens in oral therapy for bacterial diarrhea.One hundred ninety-one US students with diarrhea acquired in Mexico received 100 mg of aztreonam or matching placebo three times a day for 5 days. Stools were cultured for bacterial enteropathogens before and after therapy.We studied US (...) students who acquired diarrhea in Mexico (travelers' diarrhea) in view of the high frequency of bacterial agents in this setting.We examined time of clinical recovery, treatment failures, adverse experiences, and microbiologic eradication from stool of the etiologic agent in subjects randomized to receive aztreonam or placebo.Aztreonam reduced the average duration of diarrhea compared with the placebo: for all cases, by 40 hours (P much less than .01); for those with enterotoxigenic Escherichia coli

1992 JAMA Controlled trial quality: uncertain

19. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. (Abstract)

Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. B-subunit/whole-cell cholera vaccine (BS-WC) has been shown to give Bangladeshi mothers and children only 3 months' protection against severe diarrhoea due to enterotoxigenic Escherichia coli (ETEC). Since a long-lasting effect is not necessary for protection against travellers' diarrhoea, a prospective double-blind study was conducted among tourists who went to Morocco from Finland. 307 tourists received two oral (...) doses of BS-WC, whereas 308 controls received a placebo before departure. A research team went out with tourists and a laboratory for enteric pathogens was set up on location. A faecal specimen was taken from 100 randomly selected subjects before departure, from all travellers with diarrhoea, and routinely after return. Enteropathogenic bacteria were not isolated from any of the pre-departure specimens but were present during or after the holiday in 47% of tourists with travellers' diarrhoea

1991 Lancet Controlled trial quality: uncertain

20. Treatment of traveler's diarrhea with sulfamethoxazole and trimethoprim and loperamide. (Abstract)

Treatment of traveler's diarrhea with sulfamethoxazole and trimethoprim and loperamide. In a randomized, double-blind, placebo-controlled trial, 227 US adults with acute diarrhea in Mexico received a single dose of sulfamethoxazole and trimethoprim (1600/320 mg) or 3 days of therapy with loperamide hydrochloride (4-mg loading dose, then 2 mg orally after each loose stool), sulfamethoxazole-trimethoprim (800/160 mg orally twice daily), or the combination of both. Subjects treated (...) ). The combination of sulfamethoxazole-trimethoprim plus loperamide can be highly recommended for the treatment of most patients with traveler's diarrhea.

1990 JAMA Controlled trial quality: predicted high